Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq ... marking a significant milestone in continuous glucose monitoring. This study represents the first real-time, continuous ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq ... marking a significant milestone in continuous glucose monitoring. This study represents the first real-time, continuous ...

Glucotrack, Inc. is dedicated to developing innovative technologies for individuals with diabetes, with a current focus on a long-term implantable continuous blood glucose monitoring system.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose ...